<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 06 May 2021 07:24:42 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>最新FDA官网使用指南图解</title><link>https://mp.weixin.qq.com/s/Yra9fuDTGGA92Stsn_Ge7g</link><description></description><content:encoded><![CDATA[最新FDA官网使用指南图解]]></content:encoded><pubDate>Wed, 05 May 2021 18:40:23 +0800</pubDate></item><item><title>生物药的研发与申报详细讲解</title><link>https://mp.weixin.qq.com/s/s9SQ8P28_I5fIAWZqVm6eQ</link><description></description><content:encoded><![CDATA[生物药的研发与申报详细讲解]]></content:encoded><pubDate>Wed, 05 May 2021 18:40:23 +0800</pubDate></item><item><title>《真实世界研究统计分析方法》梳理</title><link>https://mp.weixin.qq.com/s/ddisH422USN1FUy5YaXung</link><description></description><content:encoded><![CDATA[《真实世界研究统计分析方法》梳理]]></content:encoded><pubDate>Wed, 05 May 2021 18:40:23 +0800</pubDate></item><item><title>最全新药研发流程</title><link>https://mp.weixin.qq.com/s/mOV-DAJAA27Y2KguyHDDtQ</link><description></description><content:encoded><![CDATA[最全新药研发流程]]></content:encoded><pubDate>Wed, 05 May 2021 18:40:23 +0800</pubDate></item><item><title>CDE/ ICH指导原则实施情况视频回放</title><link>https://mp.weixin.qq.com/s/RAo8C7wXsLb3ddAGWRdzUQ</link><description></description><content:encoded><![CDATA[CDE/ ICH指导原则实施情况视频回放]]></content:encoded><pubDate>Thu, 29 Apr 2021 20:55:13 +0800</pubDate></item><item><title>抗体药物偶联物治疗恶性肿瘤临床应用专家共识（2020版）</title><link>https://mp.weixin.qq.com/s/hiMp46tIzEpTEapzV3tQ6g</link><description></description><content:encoded><![CDATA[抗体药物偶联物治疗恶性肿瘤临床应用专家共识（2020版）]]></content:encoded><pubDate>Thu, 29 Apr 2021 20:55:13 +0800</pubDate></item><item><title>药品研发中的原辅料相容性实验总结</title><link>https://mp.weixin.qq.com/s/GZRjdOYImPJwIcySSC8MZw</link><description></description><content:encoded><![CDATA[药品研发中的原辅料相容性实验总结]]></content:encoded><pubDate>Wed, 28 Apr 2021 20:01:39 +0800</pubDate></item><item><title>CDE解答化药共性问题-仿制药篇</title><link>https://mp.weixin.qq.com/s/VwOr4-6Uc2z8PSTREXCFEw</link><description></description><content:encoded><![CDATA[CDE解答化药共性问题-仿制药篇]]></content:encoded><pubDate>Wed, 28 Apr 2021 20:01:39 +0800</pubDate></item><item><title>FDA 复杂仿制药的监管现状研究</title><link>https://mp.weixin.qq.com/s/AtcQmBtykkqGCGsl-LZRMw</link><description></description><content:encoded><![CDATA[FDA 复杂仿制药的监管现状研究]]></content:encoded><pubDate>Wed, 28 Apr 2021 20:01:39 +0800</pubDate></item><item><title>原料药工艺研究与控制-CTD格式的基本要求与解读-PPT</title><link>https://mp.weixin.qq.com/s/mkb3EiXR3qJyBGBY82iNuw</link><description></description><content:encoded><![CDATA[原料药工艺研究与控制-CTD格式的基本要求与解读-PPT]]></content:encoded><pubDate>Tue, 27 Apr 2021 19:18:48 +0800</pubDate></item><item><title>新药研发之重新定义DLT(剂量限制性毒性）</title><link>https://mp.weixin.qq.com/s/GfoD6If_YXQXgnmvRZjWOw</link><description></description><content:encoded><![CDATA[新药研发之重新定义DLT(剂量限制性毒性）]]></content:encoded><pubDate>Tue, 27 Apr 2021 19:18:48 +0800</pubDate></item><item><title>中国医药类大学排名公布</title><link>https://mp.weixin.qq.com/s/deMnsavUKUZRQ2iK3Chusw</link><description></description><content:encoded><![CDATA[中国医药类大学排名公布]]></content:encoded><pubDate>Tue, 27 Apr 2021 07:40:54 +0800</pubDate></item><item><title>做了这么多稳定性分析，你可能依然不懂这些问题！</title><link>https://mp.weixin.qq.com/s/Jr_TLAQNhR6wluKC01xO2A</link><description></description><content:encoded><![CDATA[做了这么多稳定性分析，你可能依然不懂这些问题！]]></content:encoded><pubDate>Tue, 27 Apr 2021 07:40:54 +0800</pubDate></item><item><title>CDK4/6抑制剂的江湖，新药还是仿药的抉择</title><link>https://mp.weixin.qq.com/s/22ywxpKe1BI-m-emwFSpEA</link><description></description><content:encoded><![CDATA[CDK4/6抑制剂的江湖，新药还是仿药的抉择]]></content:encoded><pubDate>Tue, 27 Apr 2021 07:40:54 +0800</pubDate></item><item><title>抗乳腺癌双靶点药物研究进展</title><link>https://mp.weixin.qq.com/s/je2RMCrg6NHoPlBY3ZByWg</link><description></description><content:encoded><![CDATA[抗乳腺癌双靶点药物研究进展]]></content:encoded><pubDate>Sun, 25 Apr 2021 19:53:08 +0800</pubDate></item><item><title>最新发布 化妆品注册备案资料提交技术指南（试行）</title><link>https://mp.weixin.qq.com/s/IbiyqiYUuDPtBxlmdmZWRA</link><description></description><content:encoded><![CDATA[最新发布 化妆品注册备案资料提交技术指南（试行）]]></content:encoded><pubDate>Sun, 25 Apr 2021 19:53:08 +0800</pubDate></item><item><title>高瓴重仓引进的ADC,美国获批（临床到获批仅5年）</title><link>https://mp.weixin.qq.com/s/HhvLd2PM8aNQAs7oPTY6CQ</link><description></description><content:encoded><![CDATA[高瓴重仓引进的ADC,美国获批（临床到获批仅5年）]]></content:encoded><pubDate>Sun, 25 Apr 2021 19:53:08 +0800</pubDate></item><item><title>百济神州2020年业绩推介PPT</title><link>https://mp.weixin.qq.com/s/UhBl9cTzmTl3mD0btJTLMw</link><description></description><content:encoded><![CDATA[百济神州2020年业绩推介PPT]]></content:encoded><pubDate>Sun, 25 Apr 2021 19:53:08 +0800</pubDate></item><item><title>CDE/中检院：公开招聘57名工作人员</title><link>https://mp.weixin.qq.com/s/4fROu_MvdPFYYL1dqfH43g</link><description></description><content:encoded><![CDATA[CDE/中检院：公开招聘57名工作人员]]></content:encoded><pubDate>Sat, 24 Apr 2021 18:53:49 +0800</pubDate></item><item><title>深度解读分析方法学验证各项关键指标要求</title><link>https://mp.weixin.qq.com/s/cgAMPoPac4rcDNTjcBfgcA</link><description></description><content:encoded><![CDATA[深度解读分析方法学验证各项关键指标要求]]></content:encoded><pubDate>Sat, 24 Apr 2021 18:53:49 +0800</pubDate></item></channel></rss>